SOPHIA ANTIPOLIS, France, January 4, 2023 │ An alternative synthetic mRNA platform — self-amplifying RNA (saRNA)— for vaccines may allow smaller doses of vaccines to be administered. Well positioned on this technology, Arcturus Therapeutics, a San Diego-based company founded in 2013, has a self-amplifying RNA vaccine pipeline for SARS-CoV-2 (COVID-19) and influenza. In December 2022,[…]
SOPHIA ANTIPOLIS, France – November 29, 2022 │ KnowMade has identified high recent IP activity in the field of self-amplifying RNA vaccines. This activity could be the sign of an upcoming revolution in the RNA vaccine market. Self-amplifying RNA is a next-generation platform for mRNA vaccines Compared with traditional vaccines (live-attenuated, inactivated, recombinant etc.), effective[…]
SOPHIA ANTIPOLIS, France – September 12, 2022 │ KnowMade recaps and details key patent information in Moderna’s lawsuit against Pfizer BioNTech, regarding the mRNA technology used in their COVID-19 vaccines. Patent infringement battles start Since the COVID-19 pandemic appears to be under control, companies developing mRNA are starting to enforce their IP rights. Among the[…]
SOPHIA ANTIPOLIS, France – August 09, 2022 | KnowMade noticed recent patenting activity in the field of circular mRNA therapeutics, inspiring us to publish a brief statement about this therapeutic technology. What is a circular mRNA? CircRNA structure & function The first known circular RNA (CircRNA) function is a regulatory function (through miRNA regulation, transcription regulation,[…]